Factors Favoring the Toxic Effects of Metformin in Subjects with Type 2 Diabetes in Two Referral Hospital in Douala, Cameroon

Introduction: The Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas thiazolidinediones, incretin-based drugs, sodium/glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin is the most used anti-hyperg...

Full description

Saved in:
Bibliographic Details
Published inJournal of Advances in Medical and Pharmaceutical Sciences pp. 38 - 49
Main Authors Manaoda, Antoine Vayaraï, Fuh, Azinwi Ngumsi, Yinyang, Jacques, Ngene, Jean Pierre, Loe, Gisele Etame, Adiogo, Dieudonné
Format Journal Article
LanguageEnglish
Published 26.03.2022
Online AccessGet full text

Cover

Loading…
Abstract Introduction: The Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas thiazolidinediones, incretin-based drugs, sodium/glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin is the most used anti-hyperglycemic agent for the treatment of Type 2 Diabetes Mellitus. It is considered as a very good drug, with low risk and high benefit. The Metformin liver and pancreatic intoxication can be due to massive ingestion or to a progressive accumulation due to renal failure, hence an elevated blood amylase and transaminases levels. Fatal cases due to metformin intoxication have been described. Methods: The study was an analytical cross sectional study which was carried out in the Douala General Hospital and the Douala Laquintinie Hospital from the 1st of March 2021 to the 30th of May 2021. Our study population included type 2 diabetic patients above 40years of age who are strictly on oral antidiabetic drugs who came to consult in the Douala General Hospital and the Douala Laquintinie Hospital, the exclusion criteria were; Patients infected with hepatitis A, B or hepatitis C, diabetic patients suffering from other pathologies like fatty liver disease and cirrhosis, liver cancer and others, patients suffering from terminal renal failure, patients who have been on NSAI drugs for long period and also taking alcohol or those with hemolyzed blood. For ethical consideration, after presenting and filling of the consent form, 5ml of blood was collected from each participant for the analyses, serum was conserved at a temperature of -15 to -20oC and the samples were finally analyzed in 2 series on the Biotecnica 1500 chemistry analyzer. Statistical analysis was done on Microsoft Excel 2013 version. Results: A total of 102 participants were enrolled, female gender was dominant, and the mean age was 69 years. Most of participants felt under neurological clinical effects (tiredness, dizziness, and tingling sensation). We had an average GOT of 28.3, with a minimum of 7.0 and a maximum of 207, an average GPT of 19.8 with a minimum of 5.9 and a maximum of 90.7 and an average amylase was 45.7 with a minimum value of 11.5 and a maximum value of 470. On the other hand, our average GFR was 74.3 with a minimum of 12.8 and a maximum of 153.2. From the study population, 90 where on metformin  among which 79 were on stages 2-5 of kidney failure. Conclusion: This study highlights the risk of liver toxicity for diabetic patient under metformin surfing from renal failure. 
AbstractList Introduction: The Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas thiazolidinediones, incretin-based drugs, sodium/glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin is the most used anti-hyperglycemic agent for the treatment of Type 2 Diabetes Mellitus. It is considered as a very good drug, with low risk and high benefit. The Metformin liver and pancreatic intoxication can be due to massive ingestion or to a progressive accumulation due to renal failure, hence an elevated blood amylase and transaminases levels. Fatal cases due to metformin intoxication have been described. Methods: The study was an analytical cross sectional study which was carried out in the Douala General Hospital and the Douala Laquintinie Hospital from the 1st of March 2021 to the 30th of May 2021. Our study population included type 2 diabetic patients above 40years of age who are strictly on oral antidiabetic drugs who came to consult in the Douala General Hospital and the Douala Laquintinie Hospital, the exclusion criteria were; Patients infected with hepatitis A, B or hepatitis C, diabetic patients suffering from other pathologies like fatty liver disease and cirrhosis, liver cancer and others, patients suffering from terminal renal failure, patients who have been on NSAI drugs for long period and also taking alcohol or those with hemolyzed blood. For ethical consideration, after presenting and filling of the consent form, 5ml of blood was collected from each participant for the analyses, serum was conserved at a temperature of -15 to -20oC and the samples were finally analyzed in 2 series on the Biotecnica 1500 chemistry analyzer. Statistical analysis was done on Microsoft Excel 2013 version. Results: A total of 102 participants were enrolled, female gender was dominant, and the mean age was 69 years. Most of participants felt under neurological clinical effects (tiredness, dizziness, and tingling sensation). We had an average GOT of 28.3, with a minimum of 7.0 and a maximum of 207, an average GPT of 19.8 with a minimum of 5.9 and a maximum of 90.7 and an average amylase was 45.7 with a minimum value of 11.5 and a maximum value of 470. On the other hand, our average GFR was 74.3 with a minimum of 12.8 and a maximum of 153.2. From the study population, 90 where on metformin  among which 79 were on stages 2-5 of kidney failure. Conclusion: This study highlights the risk of liver toxicity for diabetic patient under metformin surfing from renal failure. 
Author Loe, Gisele Etame
Fuh, Azinwi Ngumsi
Manaoda, Antoine Vayaraï
Ngene, Jean Pierre
Adiogo, Dieudonné
Yinyang, Jacques
Author_xml – sequence: 1
  givenname: Antoine Vayaraï
  surname: Manaoda
  fullname: Manaoda, Antoine Vayaraï
– sequence: 2
  givenname: Azinwi Ngumsi
  surname: Fuh
  fullname: Fuh, Azinwi Ngumsi
– sequence: 3
  givenname: Jacques
  surname: Yinyang
  fullname: Yinyang, Jacques
– sequence: 4
  givenname: Jean Pierre
  surname: Ngene
  fullname: Ngene, Jean Pierre
– sequence: 5
  givenname: Gisele Etame
  surname: Loe
  fullname: Loe, Gisele Etame
– sequence: 6
  givenname: Dieudonné
  surname: Adiogo
  fullname: Adiogo, Dieudonné
BookMark eNqdj81qwkAUhYeiUNv6CIX7ALWZv6Ku1eCmG5v9MAl3dCTJDTOj1kXfvYkU2nUvB-6Bc87ie2Cjllpk7Fnw1-Vc6exomy5mkkuZnaX2QnG5EHdsItVSz0R_oz_-nk1j9CXXeq6VlIsJ-8ptlShEyO2Zgm_3kA4IBX36CjbOYZUikIN3TI5C41vo9XEqj7fg4tMBimuHIGHtbYkJ41AoLgQ7dBiCrWFLsfOpN32wppOt7QusbIOBqH1iY2friNOf_8je8k2x2s6qQDEGdKYLvrHhagQ3A6654ZoB1_ziqv_uvgG20mRt
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.9734/jamps/2022/v24i130281
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
EISSN 2394-1111
EndPage 49
ExternalDocumentID 10_9734_jamps_2022_v24i130281
GroupedDBID AAYXX
CITATION
M~E
ID FETCH-crossref_primary_10_9734_jamps_2022_v24i1302813
ISSN 2394-1111
IngestDate Fri Aug 23 01:19:29 EDT 2024
IsPeerReviewed false
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-crossref_primary_10_9734_jamps_2022_v24i1302813
ParticipantIDs crossref_primary_10_9734_jamps_2022_v24i130281
PublicationCentury 2000
PublicationDate 2022-03-26
PublicationDateYYYYMMDD 2022-03-26
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-26
  day: 26
PublicationDecade 2020
PublicationTitle Journal of Advances in Medical and Pharmaceutical Sciences
PublicationYear 2022
SSID ssib044743228
Score 4.45065
Snippet Introduction: The Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas...
SourceID crossref
SourceType Aggregation Database
StartPage 38
Title Factors Favoring the Toxic Effects of Metformin in Subjects with Type 2 Diabetes in Two Referral Hospital in Douala, Cameroon
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8JAEN4gXrwYjRrf2YM3RG27C3IkSkNIIB6q8dYsddEabQ1SVBL9p_4XZ_bRolEjJqSQbRmazsfs7Mw3s4TswZqiL64AvAPp8Cqr9-EvxcAY8qjGHVmHCYdj7XC3V2ufs84lvyyV3qdYS9mofxBNvq0r-Y9WYQz0ilWyM2g2FwoD8Bn0C0fQMBz_pGPfbJbji7Hm0aEXGaTPcVRpFTyNrhyhZxorTiMYilt1QgVgAx2APbUBWLggeEorqvvscGpXETwBrra4E5okci_B4U5-cmw1rUBJs3kgVZNw8yl8bqxK7tMjESe9EqajQYre74V4EUOhcvk5AdnPVCCoOYmTp7jSu87uH-PcdMXJi4l_d0SEM14e64ZnqLMFmHk4A1_AkH5NwAPWykdeVVfVa7uIm7lXHWuj5Tdj2hbrrjFmVtd9Ub_OF426x_Q-BZh18fHX4G3sshjzucdOMUlaYsCXuTNnNMJaCoWFSlSIgsJCzByZd8EOIuOw-9ay5o4x8N5ctftvfvu6xgwlHSpJGJtyDwtJU97TlBsULJFFo2ba1GBcJiWZrJBXA0RqgUgBiFQBkRog0nRAcyBSeFkgUgQiRSBSl1og4gUARGqBSC0Q8YQG4j61MFwl3G8FJ-2qvefwQbdQCX99XN4aKSdpItcJxe5ITPBISI-zQUM0PBbBGnuAhD3u1ZwNcjCb7M1Zv7BFFgoQbpPyaJjJHfBDR_1dpc0PwxiNYg
link.rule.ids 315,783,787,27938,27939
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+Favoring+the+Toxic+Effects+of+Metformin+in+Subjects+with+Type+2+Diabetes+in+Two+Referral+Hospital+in+Douala%2C+Cameroon&rft.jtitle=Journal+of+Advances+in+Medical+and+Pharmaceutical+Sciences&rft.au=Manaoda%2C+Antoine+Vayara%C3%AF&rft.au=Fuh%2C+Azinwi+Ngumsi&rft.au=Yinyang%2C+Jacques&rft.au=Ngene%2C+Jean+Pierre&rft.date=2022-03-26&rft.issn=2394-1111&rft.eissn=2394-1111&rft.spage=38&rft.epage=49&rft_id=info:doi/10.9734%2Fjamps%2F2022%2Fv24i130281&rft.externalDBID=n%2Fa&rft.externalDocID=10_9734_jamps_2022_v24i130281
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2394-1111&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2394-1111&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2394-1111&client=summon